Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


We can stack odds in our favour on risky events

6 January 2012

Dr John MacIntosh (UCL Institute for Security and Resilience Studies) talks about the FuturICT project, and how it is improving our understanding of risk and uncertainty in dynamic networks. Read the full Financial Times (£) article...